G. Yancey Gillespie, Ph.D.
|Immunology, Surgery||University of Alabama, Birmingham, Birmingham, AL, United States|
Area:cytosine deaminase, UPRT, PNP; HSV that include TNFa, IL-2, IL-4, IL-5, IL-10, IL12, IL-16
Google:"G. Yancey Gillespie"
Mean distance: 106866
ParentsSign in to add mentor
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Stackhouse CT, Anderson JC, Yue Z, et al. (2022) An in vivo model of glioblastoma radiation resistance identifies long non-coding RNAs and targetable kinases. Jci Insight|
|Boyd NH, Tran AN, Bernstock JD, et al. (2021) Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 11: 665-683|
|Chambers MR, Bentley RT, Crossman DK, et al. (2020) The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery. 7: 59|
|Bernstock JD, Vicario N, Rong L, et al. (2019) A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. Oncoimmunology. 8: e1678921|
|Stackhouse CT, Rowland JR, Shevin RS, et al. (2019) A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening. Cells. 8|
|Totsch SK, Schlappi C, Kang KD, et al. (2019) Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene|
|Sin-Chan P, Mumal I, Suwal T, et al. (2019) A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 36: 51-67.e7|
|Bernstock JD, Vicario N, Li R, et al. (2019) Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. Cancer Gene Therapy|
|Stackhouse C, Gillespie GY, Willey C. (2019) Dres-04. Long Non-Coding Rnas In Glioblastoma Tumor Recurrence And Therapy Resistance Neuro-Oncology. 21|
|Friedman GK, Bernstock JD, Chen D, et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports. 8: 13930|